Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or
the “Company”), a clinical-stage biotechnology company that
develops novel immunotherapies to transform cancer care, is pleased
to report unprecedented activity of its next generation,
personalized, off-the-shelf, cell-based breast and prostate cancer
immunotherapies at the 2023 Society for Immunotherapy of Cancer
(SITC) annual meeting. These novel immunotherapies have been shown
to activate the immune system through multiple mechanisms including
adaptive responses of naïve (resting) T cells and innate responses
of dendritic cells and natural killer (NK) cells leading to
enhanced clinical efficacy and prevention of immune escape.
BriaCell’s current lead candidate, Bria-IMT™,
has enhanced efficacy in human leucocyte (HLA) matched patients
(LINK) and led to the development of Bria-OTS™, an off the shelf
personalized immunotherapy providing HAL matched targeting to
>99% of the US population.
“We are extremely excited with our findings
confirming unprecedented immune system responses to our novel next
generation breast and prostate cancer immunotherapies - designed
with additional immune activating components for superior
efficacy,” stated Dr. William V. Williams, BriaCell’s President
& CEO. “We expect our novel immunotherapies to boost the immune
system in cancer patients leading to tumor destruction. We believe
that our technology represents a significant advancement in the
field of oncology and personalized immunotherapy.”
BriaCell’s poster presentation highlights the
development details and activities of BriaCell’s next generation
off-the-shelf personalized immunotherapies for breast and prostate
cancers.
Abstract Title: Development and
Mechanism of Action of a Novel Cellular Immunotherapeutic Platform
for the Treatment of Advanced Solid Tumors
Abstract Number:
419Location: San Diego Convention Center, San
Diego, CASession Date and Time: Friday November 3,
2023 9:00 AM - 6:00 PMImmune system activation by
BriaCell’s next generation personalized off-the-shelf
immunotherapy
BriaCell has developed next generation,
cell-based, personalized immunotherapies, Bria-OTS+™ (for breast
cancer) and Bria-PROS+™ (for prostate cancer) that produce immune
system activating molecules e.g., antigen presenting cell
components and granulocyte macrophage colony stimulating factor
(GM-CSF), as well as newly added immune system activating factors
such as costimulatory molecules and cytokines.
Potential advantages of BriaCell’s next
generation personalized off-the-shelf immunotherapies include:
- Precision Therapy:
Bria-OTS+™ cell lines are precisely matched to individual patients
based on their HLA antigens, encompassing over 99% of the U.S.
population. This personalized approach would provide optimal
compatibility and effectiveness of cancer immunotherapy.
- Favorable Safety
Profile: Bria-OTS+™ therapies are expected to avoid the
severe and potentially life-threatening adverse events often
associated with current treatments.
- Rapid, Cost-Effective
Treatments: BriaCell OTS+™ therapies are produced for
“off-the-shelf” use. This novel approach allows for the immediate
administration of immunotherapy following standard patient HLA
genotyping. This streamlined process eliminates individualized
manufacturing requirements and may offer efficient and
cost-effective personalized treatment options to cancer patients in
need.
- Potent Immune System
Activation: BriaCell’s data has shown unprecedented broad
immune system responses to the next generation immunotherapies
compared with those of the earlier formulation. Additionally, our
findings confirmed that both Bria-OTS+™ and Bria-PROS+™activate
multiple components of the immune system through direct activation
of naïve (resting) T- cells as well as activation of Natural killer
(NK) cells via production of immune activating molecules including
CD86 (a co-stimulatory molecule).
- Platform
Technology: These findings support further development of
BriaCell’s platform of next-generation cancer immunotherapies for
multiple cancer types, focusing initially on breast, and prostate
cancers.
In summary, BriaCell’s novel next generation
personalized immunotherapy delivers broad immune responses against
various solid tumor models via multiple immune activating
mechanisms. BriaCell’s cell-based immunotherapies may offer
superior efficacy in addition to favorable safety profiles in
cancer patients. Importantly, the off-the-shelf (i.e.,
premanufactured) nature of our immunotherapy may shorten the time
to receive cancer treatment, and perhaps prevent disease
progression in cancer patients. BriaCell expects the administration
of personalized BRIA-OTS+™ and BRIA-PROS+™ immunotherapies,
following a rapid and routine HLA test, to provide safe and
effective treatment options for cancer patients. These findings
support BriaCell’s strategy to further develop this approach as a
platform technology with broad applications for multiple
cancers.
A copy of the poster will be posted at the
following: https://briacell.com/scientific-publications/.
In separate news, FDA has stated that BriaCell
may proceed with the clinical study of Bria-OTS™. This opens the
path to the clinic for Bria-OTS™, the first generation of
BriaCell’s personalized off-the-shelf cellular immunotherapy for
breast cancer.
“We are gratified that the FDA has opened our
IND for the first generation of Bria-OTS™,” stated Dr. William
Williams. “This will enable us to begin the process of initiating
the clinical study of Bria-OTS™ and will provide a roadmap for the
introduction of the advanced versions of our personalized
off-the-shelf cellular immunotherapies for breast cancer, prostate
cancer and other cancers. Given the very exciting data presented at
the SITC meeting, we believe that these immunotherapies have the
potential to be a game-changer in the field of cancer
treatments.”
About BriaCell Therapeutics
Corp.
BriaCell is an immuno-oncology-focused
biotechnology company developing targeted and effective approaches
for the management of cancer. More information is available at
https://briacell.com/.
Safe Harbor
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” “will,” “would,” or the negative of
these words or other similar expressions, although not all
forward-looking statements contain these words. Examples of
forward-looking statements in this news release include statements
that the Company makes regarding: further development of BriaCell’s
next generation personalized immunotherapy platform with broad
applications for multiple cancers; whether BriaCell’s novel
immunotherapies may boost the immune system in cancer patients
leading to tumor destruction; whether BriaCell’s technology
represents a significant advancement in the field of oncology and
personalized immunotherapy; any potential advantages of BriaCell’s
next generation personalized off-the-shelf immunotherapies (for
example: precision therapy, favorable safety profile, rapid and
cost-effective treatments, potent immune system activation, and the
development of the platform technology); whether BriaCell’s
cell-based immunotherapies may offer superior efficacy in addition
to favorable safety profiles in cancer patients; whether the
off-the-shelf (i.e., premanufactured) nature of BriaCell’s
immunotherapy may shorten the time to receive cancer treatment, and
perhaps prevent disease progression in cancer patients; the
expectation that the administration of personalized BRIA-OTS+™ and
BRIA-PROS+™ immunotherapies, following a rapid and routine HLA
test, may provide safe and effective treatment options for cancer
patients; whether BriaCell may begin the process of initiating the
clinical study of Bria-OTS™; and whether BriaCell’s immunotherapies
have the potential to be a game-changer in the field of cancer
treatments.
Forward-looking statements are based on
BriaCell’s current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict.
Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
These and other risks and uncertainties are described more fully
under the heading “Risks and Uncertainties” in the Company’s most
recent Management’s Discussion and Analysis, under the heading
“Risk Factors” in the Company’s most recent Annual Information
Form, and under “Risks and Uncertainties” in the Company’s other
filings with the Canadian securities regulatory authorities and the
U.S. Securities and Exchange Commission, all of which are available
under the Company’s profiles on SEDAR at www.sedar.com and on EDGAR
at www.sec.gov. Forward-looking statements
contained in this announcement are made as of this date, and
BriaCell Therapeutics Corp. undertakes no duty to update such
information except as required under applicable law.
Neither Toronto Stock Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Toronto Stock Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Contact Information
Company Contact:William V.
Williams, MDPresident &
CEO1-888-485-6340info@briacell.com
Media Relations:Jules
AbrahamDirector of Public RelationsCORE
IR917-885-7378julesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (NASDAQ:BCTXW)
Historical Stock Chart
From Jun 2024 to Jul 2024
BriaCell Therapeutics (NASDAQ:BCTXW)
Historical Stock Chart
From Jul 2023 to Jul 2024